Shopping Cart
- Remove All
- Your shopping cart is currently empty
BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $48 | In Stock | |
5 mg | $116 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $433 | In Stock | |
50 mg | $638 | In Stock | |
100 mg | $892 | In Stock | |
1 mL x 10 mM (in DMSO) | $158 | In Stock |
Description | BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively. |
Targets&IC50 | PI3Kγ:38 nM, PI3Kβ:63 nM, PI3Kα:4 nM |
In vitro | Growth inhibition experiment showed that BGT226 had antitumor activity. BGT226 significantly inhibited cell growth with IC50 < 20 nM. BGT226 also induced cancer cell apoptosis at nanomolar concentration, IC50 ≤ 25 nM[1][2][3]. |
In vivo | BGT226 significantly delayed tumor growth on the transplanted tumor animal model. This effect was dose-dependent, accompanied by inhibition of p-p70 S6 kinase cytoplasmic expression and autophagy body formation[2]. |
Alias | NVP-BGT226, BGT226 free base |
Molecular Weight | 534.53 |
Formula | C28H25F3N6O2 |
Cas No. | 915020-55-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 65 mg/ml (121.6 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.